NCT06933914View on ClinicalTrials.gov

Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
DRUG

MY008211A tablets

Participants will receive MY008211A at a dose of 400 mg orally b.i.d

Trial Locations (1)

300020

RECRUITING

Chinese Academy of Medical Sciences Hematology Hospital (Institute of Hematology, Chinese Academy of Medical Sciences), Tianjin

All Listed Sponsors
lead

Wuhan Createrna Science and Technology Co., Ltd

INDUSTRY